| 1 |
28797106 | The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. | 2017 |
1 |
| 2 |
26644819 | Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development. | 2015 Nov 28 |
1 |
| 3 |
22585728 | Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. | 2012 Jul |
1 |
| 4 |
20830599 | Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. | 2011 Mar |
1 |
| 5 |
18551609 | Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma. | 2008 Aug |
4 |
| 6 |
17444854 | Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. | 2007 May |
4 |
| 7 |
16136646 | Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. | 2005 Sep |
1 |